Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04116502
Title MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (MITHRIDATE)
Acronym MITHRIDATE
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors University of Birmingham
Indications
Therapies
Age Groups: adult | senior
Covered Countries GBR

Additional content available in CKB BOOST